About Contact Us Careers

Acinetobacter Pneumonia Therapeutics companies

  • Report ID: 6546
  • Published Date: Oct 11, 2024
  • Report Format: PDF, PPT

Companies Dominating the Acinetobacter Pneumonia Therapeutics Landscape

    The global Acinetobacter pneumonia therapeutics market is positioned to witness a profitable growth curve during the forecast period. Key market players are investing in improving their distribution channels, research on multi drug resistant bacteria, clinical trials and drug approvals to treat bacterial pneumonia. Additionally, global players are partnering with local players to gain access to niche markets and improve revenue shares. Countries such as China, India, Japan, South Korea, and Australia are investing in their healthcare sector and increasing awareness on Acinetobacter baumannii infections which plays a critical role in the acinetobacter pneumonia therapeutics market’s growth.

    Here are some key players in the acinetobacter pneumonia therapeutics market:

    • Shionogi Inc.
      • Company Overview 
      • Business Strategy 
      • Key Product Offerings 
      • Financial Performance 
      • Key Performance Indicators 
      • Risk Analysis 
      • Recent Development 
      • Regional Presence 
      • SWOT Analysis 
    • AstraZeneca PLC
    • Pfizer Inc.
    • Sanofi
    • Bayer AG
    • Merck & Co., Ltd.
    • GlaxoSmithKline PLC
    • Novartis AG
    • Zimmer Biomet

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

The global acinetobacter pneumonia therapeutics market attained USD 496.9 million in 2024 and is poised to register a profitable CAGR of 6.4% during the forecast period, i.e., 2025-2037.

The global acinetobacter pneumonia therapeutics market registered a profitable valuation of USD 496.9 million in 2024 and is projected to attain a valuation of USD 1.1 billion by 2037 with a CAGR if 6.4% during the forecast period, i.e., 2025-2037.

The major players in the market are Shionogi Inc., AstraZeneca PLC, Pfizer Inc, Sanofi, Bayer AG, Merck & Co., Ltd., GlaxoSmithKline PLC, Novartis AG, Zimmer Biomet, and others.

The AC segment is poised to dominate the revenue share with a 51.6% market share during the forecast period. The segment's growth is attributed to its compatibility with existing infrastructure and increasing adoption due to its cost-efficiency in power protection systems. The parenteral segment dominated the market share in 2024 with a whooping 73.5% revenue share. The segment's growth is owed to large-scale application in severe cases of hospital acquired pneumonia.

North America is poised to register the highest market share in the global market with a revenue share of 46.1% by 2037. The growth of the market in the region is attributed to a robust healthcare infrastructure and regulatory ecosystem facilitating research on multi drug resistant bacteria.
Inquiry Before Buying Request Free Sample PDF

Copyright @ 2026 Research Nester. All Rights Reserved.

footer-bottom-logos